Literature DB >> 3428348

The pharmacokinetics of ketoconazole after chronic administration in adults.

N R Badcock1, F D Bartholomeusz, D B Frewin, L N Sansom, J G Reid.   

Abstract

We have studied the pharmacokinetics of the anti-mycotic ketoconazole in seven patients who took it for 1-6 months at a dose of 200 mg daily. The mean elimination half-life of the drug was 3.3 h, and although the ketoconazole was given only once daily, a satisfactory clinical response was obtained in all seven individuals. Only a small fraction of the absorbed drug (mean 0.22%) was excreted unchanged in the urine, suggesting almost complete metabolism. Our results support the concept that anti-mycotic activity in the tissues continues after the plasma drug concentration has fallen below a critical level. Our results also support the concept of a change in pharmacokinetics with chronic dosing.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3428348     DOI: 10.1007/BF00544251

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Pharmacokinetics of ketoconazole in normal subjects.

Authors:  T K Daneshmend; D W Warnock; A Turner; C J Roberts
Journal:  J Antimicrob Chemother       Date:  1981-10       Impact factor: 5.790

Review 2.  Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections.

Authors:  R C Heel; R N Brogden; A Carmine; P A Morley; T M Speight; G S Avery
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

3.  Influence of food on the pharmacokinetics of ketoconazole.

Authors:  T K Daneshmend; D W Warnock; M D Ene; E M Johnson; M R Potten; M D Richardson; P J Williamson
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

4.  Micro-determination of ketoconazole in plasma or serum by high-performance liquid chromatography.

Authors:  N R Badcock
Journal:  J Chromatogr       Date:  1984-03-09

5.  Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers.

Authors:  Y C Huang; J L Colaizzi; R H Bierman; R Woestenborghs; J Heykants
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

6.  Laboratory and clinical assessment of ketoconazole in deep-seated mycoses.

Authors:  E Drouhet; B Dupont
Journal:  Am J Med       Date:  1983-01-24       Impact factor: 4.965

7.  Treatment of coccidioidomycosis with ketoconazole: clinical and laboratory studies of 18 patients.

Authors:  J R Graybill; D Lundberg; W Donovan; H B Levine; M D Rodriguez; D J Drutz
Journal:  Rev Infect Dis       Date:  1980 Jul-Aug

8.  Disposition of ketoconazole, an oral antifungal, in humans.

Authors:  C Brass; J N Galgiani; T F Blaschke; R Defelice; R A O'Reilly; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

9.  Impairing effect of food on ketoconazole absorption.

Authors:  P T Männistö; R Mäntylä; S Nykänen; U Lamminsivu; P Ottoila
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

Review 10.  Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use.

Authors:  J H Van Tyle
Journal:  Pharmacotherapy       Date:  1984 Nov-Dec       Impact factor: 4.705

View more
  4 in total

1.  In vitro drug-drug interactions with perospirone and concomitantly administered drugs in human liver microsomes.

Authors:  Jin Shimakura; Naoko Tani; Yoshiko Mizuno; Setsuko Komuro; Hiroshi Kanamaru
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Jan-Mar       Impact factor: 2.441

Review 2.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

3.  Impact of Composition and Morphology of Ketoconazole-Loaded Solid Lipid Nanoparticles on Intestinal Permeation and Gastroplus-Based Prediction Studies.

Authors:  Shaya Jubran Aljurbui; Afzal Hussain; Mohammad Yusuf; Mohhammad Ramzan; Obaid Afzal; Basmah Almohaywi; Sabina Yasmin; Abdulmalik Saleh Alfawaz Altamimi
Journal:  ACS Omega       Date:  2022-06-20

4.  Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine.

Authors:  L L von Moltke; D J Greenblatt; M M Cotreau-Bibbo; J S Harmatz; R I Shader
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.